Authors: Joey Rehkopf, Malte Glüsen, Sebastian Vinzens, Ingo Hantke, Matthias P. Schönermark
Tuesday 11th Nov 2025
Poster Presentation: 10:30 – 13:30
Discussion Period: 12:30 - 13:30
OBJECTIVES
Based on the G-BA rulings up until this point, patient individual therapies can be assigned as an appropriate comparator therapy (ACT) with or without explicitly stating drugs that need to be considered for the therapy. This analysis compares the impact of patient individual therapies as ACTs, with or without designated drugs, on the price levels and rebates in Germany.
METHODS
All available G-BA procedures with a patient individual therapy as an ACT were identified and analysed for drug prices, net rebates and other factors, based on whether the G-BA included designated drugs for the patient individual therapy or not. In a second step, the analysis was rerun with the exclusion of antiviral therapies.
RESULTS
152 procedures with a patient individual therapy as an ACT were identified, of which 91 procedures included designated drugs as an ACT and 61 procedures did not. In comparison, procedures with designated drugs as an ACT on average received lower additional benefit ratings (70 % vs. 54 % no added benefit) and lower price levels, as well as higher net rebates after negotiations. All 28 procedures on antiviral therapies did not include designated drugs in their ACT.
CONCLUSIONS
The most prevalent therapeutic area with drugs with a patient individual ACT is oncology. Drugs that do not need to compare themselves against designated drugs in an individual therapy seem to have a higher chance of reaching a higher additional benefit and therefore a lower rebate. This is especially important, since per “Guidance on the Scoping Process” an individualised treatment will always comprise different treatment options with designated drugs.
